Cubist Systematic Strategies, LLC Lyell Immunopharma, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.71 - $3.07 $56,277 - $101,036	-32,911 Reduced 53.37%	28,756 $64,000
Q4 2023 Feb 14, 2024	BUY	$1.39 - $2.35 $85,717 - $144,917	61,667 New	61,667 $119,000
Q1 2023 May 15, 2023	BUY	$1.97 - $3.58 $97,432 - $177,059	49,458 New	49,458 $116,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $166,842 - $249,059	30,116 New	30,116 $221,000
Q2 2022 Aug 15, 2022	SELL	$3.68 - $6.8 $179,591 - $331,853	-48,802 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.05 - $7.7 $591,264 - $901,531	-117,082 Reduced 70.58%	48,802 $246,000
Q4 2021 Feb 14, 2022	BUY	$7.13 - $15.19 $892,861 - $1.9 Million	125,226 Added 308.0%	165,884 $1.28 Million
Q3 2021 Nov 15, 2021	BUY	$11.0 - $17.95 $383,361 - $625,575	34,851 Added 600.15%	40,658 $602,000
Q2 2021 Aug 16, 2021	BUY	$15.99 - $16.89 $92,853 - $98,080	5,807 New	5,807 $94,000

122

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.